108 related articles for article (PubMed ID: 32966755)
1. Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights.
Smith JA; Harle A; Dockry R; Holt K; Russell P; Molassiotis A; Yorke J; Robinson R; Birrell MA; Belvisi MG; Blackhall F
Am J Respir Crit Care Med; 2021 Mar; 203(6):737-745. PubMed ID: 32966755
[No Abstract] [Full Text] [Related]
2. A commentary on 'Pulmonary vagus nerve transection for chronic cough after video-assisted lobectomy: A randomized controlled trial'.
Ruan ZG; Xu CY; Hua LF
Int J Surg; 2024 Apr; ():. PubMed ID: 38597401
[No Abstract] [Full Text] [Related]
3. Neurokinin-1 Receptor Inhibition and Cough.
Turner RD; Birring SS
Am J Respir Crit Care Med; 2021 Mar; 203(6):672-674. PubMed ID: 33108214
[No Abstract] [Full Text] [Related]
4. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
Zhou C; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Wu F; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J;
Lancet Respir Med; 2021 Mar; 9(3):305-314. PubMed ID: 33347829
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Cascone T; William WN; Weissferdt A; Leung CH; Lin HY; Pataer A; Godoy MCB; Carter BW; Federico L; Reuben A; Khan MAW; Dejima H; Francisco-Cruz A; Parra ER; Solis LM; Fujimoto J; Tran HT; Kalhor N; Fossella FV; Mott FE; Tsao AS; Blumenschein G; Le X; Zhang J; Skoulidis F; Kurie JM; Altan M; Lu C; Glisson BS; Byers LA; Elamin YY; Mehran RJ; Rice DC; Walsh GL; Hofstetter WL; Roth JA; Antonoff MB; Kadara H; Haymaker C; Bernatchez C; Ajami NJ; Jenq RR; Sharma P; Allison JP; Futreal A; Wargo JA; Wistuba II; Swisher SG; Lee JJ; Gibbons DL; Vaporciyan AA; Heymach JV; Sepesi B
Nat Med; 2021 Mar; 27(3):504-514. PubMed ID: 33603241
[TBL] [Abstract][Full Text] [Related]
6. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331
Spigel DR; Vicente D; Ciuleanu TE; Gettinger S; Peters S; Horn L; Audigier-Valette C; Pardo Aranda N; Juan-Vidal O; Cheng Y; Zhang H; Shi M; Luft A; Wolf J; Antonia S; Nakagawa K; Fairchild J; Baudelet C; Pandya D; Doshi P; Chang H; Reck M
Ann Oncol; 2021 May; 32(5):631-641. PubMed ID: 33539946
[TBL] [Abstract][Full Text] [Related]
7. First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1.
Reck M; Ciuleanu TE; Lee JS; Schenker M; Audigier-Valette C; Zurawski B; Linardou H; Otterson GA; Salman P; Nishio M; de la Mora Jimenez E; Lesniewski-Kmak K; Albert I; Ahmed S; Syrigos K; Penrod JR; Yuan Y; Blum SI; Nathan FE; Sun X; Moreno-Koehler A; Taylor F; O'Byrne KJ
J Thorac Oncol; 2021 Apr; 16(4):665-676. PubMed ID: 33485960
[TBL] [Abstract][Full Text] [Related]
8. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Paz-Ares L; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Sakai H; Lingua A; Salman P; Souquet PJ; De Marchi P; Martin C; Pérol M; Scherpereel A; Lu S; John T; Carbone DP; Meadows-Shropshire S; Agrawal S; Oukessou A; Yan J; Reck M
Lancet Oncol; 2021 Feb; 22(2):198-211. PubMed ID: 33476593
[TBL] [Abstract][Full Text] [Related]
9. Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Hart LL; Ferrarotto R; Andric ZG; Beck JT; Subramanian J; Radosavljevic DZ; Zaric B; Hanna WT; Aljumaily R; Owonikoko TK; Verhoeven D; Xiao J; Morris SR; Antal JM; Hussein MA
Adv Ther; 2021 Jan; 38(1):350-365. PubMed ID: 33123968
[TBL] [Abstract][Full Text] [Related]
10. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.
Morice A; Smith JA; McGarvey L; Birring SS; Parker SM; Turner A; Hummel T; Gashaw I; Fels L; Klein S; Francke K; Friedrich C
Eur Respir J; 2021 Nov; 58(5):. PubMed ID: 33986030
[TBL] [Abstract][Full Text] [Related]
11. The Airway Microbiota Modulates Effect of Azithromycin Treatment for Episodes of Recurrent Asthma-like Symptoms in Preschool Children: A Randomized Clinical Trial.
Thorsen J; Stokholm J; Rasmussen MA; Mortensen MS; Brejnrod AD; Hjelmsø M; Shah S; Chawes B; Bønnelykke K; Sørensen SJ; Bisgaard H
Am J Respir Crit Care Med; 2021 Jul; 204(2):149-158. PubMed ID: 33730519
[No Abstract] [Full Text] [Related]
12. Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies.
Yeo W; Li L; Lau TK; Lai KT; Chan VT; Wong KH; Yip CC; Pang E; Cheung M; Chan V; Kwok CC; Suen JJ; Mo FK
Cancer Biol Med; 2021 Mar; 18(3):825-32. PubMed ID: 33710814
[TBL] [Abstract][Full Text] [Related]
13. Noxious cold stimulation: pro-con perspectives on the hypothermic effect on experimentally evoked cough.
Zhong S; Fang L; Chen Z; Zhan C; de Silva SD; Lai K; Chen R
Eur Respir J; 2021 Mar; 57(3):. PubMed ID: 33707170
[No Abstract] [Full Text] [Related]
14. Reply to: Noxious cold stimulation: pro-con perspectives on the hypothermic effect on experimentally evoked cough.
Satia I; Iovoli E; Holt K; Woodcock AA; Belcher J; Smith JA
Eur Respir J; 2021 Mar; 57(3):. PubMed ID: 33707168
[No Abstract] [Full Text] [Related]
15. Adherence to Asthma Biologics: Implications for Patient Selection, Step Therapy, and Outcomes.
Maddux JT; Inselman JW; Jeffery MM; Lam RW; Shah ND; Rank MA
Chest; 2021 Mar; 159(3):924-932. PubMed ID: 33558205
[TBL] [Abstract][Full Text] [Related]
16. Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort.
Thijssen S; Wildiers H; Punie K; Beuselinck B; Clement P; Remmerie C; Berteloot P; Han S; Van Nieuwenhuysen E; Van Gorp T; Vergote I; Smeets A; Nevelsteen I; Floris G; Weltens C; Menten J; Janssen H; Laenen A; Neven P
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1041-1048. PubMed ID: 33471187
[TBL] [Abstract][Full Text] [Related]
17. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial.
Bachelot T; Filleron T; Bieche I; Arnedos M; Campone M; Dalenc F; Coussy F; Sablin MP; Debled M; Lefeuvre-Plesse C; Goncalves A; Reynier MM; Jacot W; You B; Barthelemy P; Verret B; Isambert N; Tchiknavorian X; Levy C; Thery JC; L'Haridon T; Ferrero JM; Mege A; Del Piano F; Rouleau E; Tran-Dien A; Adam J; Lusque A; Jimenez M; Jacquet A; Garberis I; Andre F
Nat Med; 2021 Feb; 27(2):250-255. PubMed ID: 33462450
[TBL] [Abstract][Full Text] [Related]
18. American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline for Management of Hereditary Breast Cancer.
Yip CH; Newman LA
JAMA Surg; 2021 Mar; 156(3):284-285. PubMed ID: 33439213
[No Abstract] [Full Text] [Related]
19. Esophagectomy With Three-Field Versus Two-Field Lymphadenectomy for Middle and Lower Thoracic Esophageal Cancer: Long-Term Outcomes of a Randomized Clinical Trial.
Li B; Zhang Y; Miao L; Ma L; Luo X; Zhang Y; Ye T; Li H; Zhang J; Li Y; Zhao K; Fan M; Zhu Z; Wang J; Xu J; Deng Y; Lu Q; Li H; Zhang Y; Pan Y; Liu S; Shao L; Sun Y; Xiang J; Hu H; Chen H
J Thorac Oncol; 2021 Feb; 16(2):310-317. PubMed ID: 33307192
[TBL] [Abstract][Full Text] [Related]
20. Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer.
de Haan R; van den Heuvel MM; van Diessen J; Peulen HMU; van Werkhoven E; de Langen AJ; Lalezari F; Pluim D; Verwijs-Janssen M; Vens C; Schellens JHM; Steeghs N; Verheij M; van Triest B
Clin Cancer Res; 2021 Mar; 27(5):1256-1266. PubMed ID: 33262140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
